RNTX Rein Therapeutics, Inc. Insider Trading

Director Von Rickenbach purchases 47,060 shares at $1.04–$1.07 (avg $1.05), tripling holdings to 62.5K shares amid -49.8% drawdown from 52-week high.

Rickenbach Josef H Von, a Director at unprofitable RNTX, executed 4 separate purchases totaling 47,060 shares for $49,560.64 between May 21–27, 2026, at prices ranging from $1.04 to $1.07. This increased his holdings by 304.5% from 15,454 to 62,514 shares. The stock is currently trading at $1.11, representing a -49.8% decline from its 52-week high of $2.21 and a -23.4% drop over the prior 30 days. The company posted $0.00 quarterly revenue and -$5.8M net income, with negative full-year profitability. The magnitude of the purchase relative to prior holdings and the execution across multiple trading days warrants attention to whether this reflects a strategic reassessment or other material considerations.

James Brian Windsor bought 25,000 shares of RNTX at $1.00 on 2026-04-30; stock now -56.0% from 52-week high at $0.96.

James Brian Windsor purchased 25,000 shares of Rein Therapeutics at $1.00, increasing his non-derivative holdings by +1221.9% from 2,046 to 27,046 shares, while retaining 150,000 shares in stock options. The company carries negative fundamentals: $-5.8M net income in its most recent full fiscal year and $0.00 revenue in the latest quarter, against a market cap of $82.1M. The stock has declined -56.0% from its 52-week high of $2.18 and -17.2% over the past 30 days. While Windsor's cross-ticker track record shows 4 prior buys with a 90d win rate of 50.00% and average 90d return of +47.6%, the current share price of $0.96 remains well below his $1.00 purchase price. The transaction reflects a substantial increase in direct equity stake despite the company's unprofitable status and the stock's recent weakness.

Voss Capital (10% owner) buys 104,183 shares of RNTX at $1.22; holdings now 926,441 shares (+12.7%). Stock -54.8% from 52-week high.

Voss Capital has executed four separate buy transactions at RNTX between 2025-10-24 and today (2025-11-14), accumulating 104,183 shares at $1.22 in this latest purchase. The stock trades 54.8% below its 52-week high of $2.70, yet the insider continues to add to its position. While Voss Capital's cross-ticker track record shows an average 90-day return of +7.8% with a 100.00% win rate across 8 prior buys at other companies, the four current trades at RNTX remain too recent to measure meaningful outcomes. The company is unprofitable (net income $-5.6M) and reported zero revenue in its latest quarter, making this an accumulation in a distressed biotech. The clustering of purchases over three weeks suggests sustained conviction despite the depressed valuation.

10% owner Voss Capital buys 306,050 shares (306.0K) across 4 transactions for $423,465.64, expanding position 157.8%

Voss Capital, a 10% beneficial owner, executed 4 separate purchases totaling 306,050 shares at a blended average price of $1.38 between October 24–28, 2025, expanding its stake from 193,950 shares to 500,000 shares (+157.8%). The purchases occurred as the stock traded near the lower end of its 52-week range ($1.08–$2.70), currently down 51.1% from its 52-week high but up 11.9% over the past 30 days. Rein Therapeutics is unprofitable (latest quarter revenue $0.00, full-year net income negative), with a market cap of $30,762,742.56—a small-cap context where concentrated ownership moves and financial distress typically carry elevated risk. Voss Capital's cross-ticker track record shows 4 prior open-market buys with 100.00% 90-day win rate and average 90-day return of 7.8%, but this baseline does not establish predictive accuracy at RNTX specifically, where this position now represents material concentration within the small float.

ALRN CEO Windsor purchased 400 shares across 2 transactions on 2024-12-05 for blended avg $2.24, marking repeat buying at deeply depressed valuations.

James Brian Windsor, President and CEO, executed 2 separate purchases totaling 400 shares for $897.61 on 2024-12-05 at $2.24–$2.25 per share. The current price of $2.12 reflects a -69.4% decline from the 52-week high of $6.93 and a -44.2% 30-day decline. This is Windsor's third open-market buy at ALRN: prior purchases on 2023-11-20 and 2023-12-15 generated 90-day returns of +138.4% and +64.1% respectively, establishing a pattern of well-timed accumulation at this ticker. Against this backdrop, Windsor's decision to purchase at current levels—near the 52-week low of $1.65—follows his demonstrated track record of open-market buying. The company remains unprofitable with negative quarterly and full-year net income, and its fundamentals offer limited conventional rationale for the purchase. The near-term price action (stock down -44.2% in 30 days) and the CEO's repeat pattern of open-market acquisition merit investor attention.